Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company, has announced its participation in three upcoming healthcare conferences in September 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company, has announced its participation in three upcoming healthcare conferences in September 2024. The company's Chair and CEO, Jasbir S. Seehra, Ph.D., will present at:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 at 4:05 p.m. ET
2. 2024 Wells Fargo Healthcare Conference on September 5 at 10:15 a.m. ET
3. 2024 Cantor Global Healthcare Conference on September 19 at 8:35 a.m. ET
All presentations will be in a fireside chat format. Archived replays will be available on the Keros website for up to 90 days after each event. Keros focuses on developing therapeutics for disorders linked to dysfunctional signaling of the TGF-ß family of proteins.
Details
News Market Reaction – KROS
The recorded move for KROS in the trading session of this news was -0.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference
- Date and Time: Wednesday, September 4, 2024 at 4:05 p.m. Eastern time
- Link: https://cc.webcasts.com/morg007/090424a_js/?entity=151_MYXXV3G
- Format: Fireside Chat Presentation
2024 Wells Fargo Healthcare Conference
- Date and Time: Thursday, September 5, 2024 at 10:15 a.m. Eastern time
- Link: https://cc.webcasts.com/well001/090424a_js/?entity=90_NG8VPD0
- Format: Fireside Chat Presentation
2024 Cantor Global Healthcare Conference
- Date and Time: Thursday, September 19, 2024 at 8:35 a.m. Eastern Time
- Link: https://wsw.com/webcast/cantor22/kros/2112021
- Format: Fireside Chat Presentation
For each presentation, an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of each event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. The Company is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ second product candidate, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension for the treatment of cardiovascular disorders. Keros’ third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.